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Background: The population-based Surveillance, Epidemiology, and
End Results (SEER) registries collect information on first-course
treatment, including surgery, chemotherapy, radiation therapy, and
hormone therapy. However, the SEER program does not release data
on chemotherapy or hormone therapy due to uncertainties regarding
data completeness. Activities are ongoing to investigate the oppor-
tunity to supplement SEER treatment data with other data sources.
Methods: Using the linked SEER-Medicare data, we examined the
validity of the SEER data to identify receipt of chemotherapy and
radiation therapy among those aged 65 and older diagnosed from
2000 to 2006 with bladder, female breast, colorectal, lung, ovarian,
pancreas, or prostate cancer and hormone therapy among men di-
agnosed with prostate cancer at age 65 or older. Treatment collected
by SEER was compared with treatment as determined by Medicare
claims, using Medicare claims as the gold standard. The k, sensi-
tivity, specificity, positive predictive values, and negative predictive
values were calculated for the receipt of each treatment modality.
Results: The overall sensitivity of SEER data to identify chemo-
therapy, radiation, and hormone therapy receipt was moderate
(68%, 80%, and 69%, respectively) and varied by cancer site, stage,
and patient characteristics. The overall positive predictive value was
high (> 85%) for all treatment types and cancer sites except chemo-
therapy for prostate cancer.
Conclusions: SEER data should not generally be used for com-
parisons of treated and untreated individuals or to estimate the
proportion of treated individuals in the population. Augmenting
SEER data with other data sources will provide the most accurate
treatment information.
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The Surveillance, Epidemiology, and End Results (SEER)program, sponsored by the National Cancer Institute
(NCI), is a system of population-based cancer registries
that currently covers approximately 28% of the US
population from geographically defined areas. In addition to
reporting national cancer statistics on incidence and survival,
the SEER registries serve as a platform for studies of
cancer-related care and health disparities. As such there is
considerable interest in treatment information for individuals
diagnosed with cancer captured in the population-based
registries. The SEER registries routinely collect data on
the first course of cancer treatment including information
on surgery, radiation therapy (RT), chemotherapy (CT), and
hormone therapy (HT). Information on surgery and RT is
reported in the publically available SEER dataset, although
several studies have reported underascertainment of RT on
the SEER data.1,2 NCI does not make data on CT and HT
publically available due to concerns about the completeness
of the information.
Persons in the SEER data who are Medicare eligible
have been matched to their Medicare claims to create the
linked SEER-Medicare data. The SEER-Medicare data in-
clude longitudinal claims, allowing for the identification of
cancer treatments from Medicare claims for cancer patients
appearing in the SEER data.3 Prior validation studies have
shown that Medicare claims can accurately identify persons
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receiving RT1,4,5 and CT.6–10 Several studies have used
Medicare claims to identify individuals who received
HT11–13 although these claims have not been validated.
Activities are ongoing at NCI to further investigate the
opportunity and benefit of using claims to supplement
treatment data. The linkage of the SEER and Medicare data
offers the opportunity to validate treatment reported on the
SEER data, using Medicare claims as the gold standard. As
an initial step, this analysis will evaluate the completeness
and validity of SEER treatment data. We compared treatment
data from SEER with Medicare claims for (1) CT among
individuals diagnosed with bladder, female breast, color-
ectal, lung, ovarian, pancreas, and prostate cancer; (2) RT
among individuals diagnosed with these cancers except
ovarian; and (3) HT among individuals diagnosed with
prostate cancer. The concordance of treatment between the 2
data sources was estimated across a number of covariates
including cancer site, stage, sex, age, race/ethnicity, geo-
graphic location, and year of diagnosis. The sensitivity,
specificity, positive predictive value (PPV), and negative
predictive value (NPV) of SEER treatment variables were
also estimated across the same covariates using Medicare
claims as the gold standard.
METHODS
Data Sources
The SEER-Medicare data used for this study included
cases reported from 17 SEER cancer registries, with the
exception of Alaska Natives. To augment available public
use of SEER data, we were able to access internal NCI data
that included information about CT and HT administration
collected by the SEER registries. This internal information
and publically available information on RT was used for
comparison to Medicare treatment information.
Individuals in the SEER data have been matched to
Medicare’s master enrollment file maintained by the Centers
for Medicare and Medicaid Services (CMS).14 For persons
reported to a SEER registry who were aged 65 or older, 94%
have been linked to Medicare and their Medicare claims
have been extracted.15–17 For this analysis, we included
claims from inpatient hospitalizations (MEDPAR), out-
patient facilities, physician claims, or durable medical
equipment (DME). These files include claims for CT, RT,
and injected HT for each beneficiary with fee-for-service
coverage.17 All Medicare claims include codes that indicate
the type of services performed. Services are reported using
the International Classification of Diseases, Ninth Revision
(ICD-9), Healthcare Common Procedure Coding System
(HCPCS), and National Drug Codes (NDCs). In general, oral
agents for CT are covered by Medicare Part D and so could
not be captured in this analysis. However, oral chemo-
therapeutic agents that are equivalent to those intravenously
administered, such as capecitabine, are covered as a part of
Medicare Part B and could be identified in our study.
Study Sample
We identified 433,415 individuals in the SEER-Medi-
care data who were diagnosed with bladder, female breast,
colorectal, lung, ovary, pancreas, or prostate cancer from
2000 to 2006 for analysis. For inclusion in our study, in-
dividuals had to be at least 65 years of age at diagnosis, have
continuous Part A, B, and fee-for-service coverage and not
be enrolled in a Health Maintenance Organization during
that year, and only have 1 cancer according to SEER data.
These criteria were implemented to ensure complete Medi-
care claims for all individuals and so that any treatment
identified using claims would be attributed to the correct
cancer. In addition, those diagnosed on autopsy or death
certificate (n = 9276) or without a known month of diagnosis
(n = 4984) were excluded. A small number of individuals
were part of the Patterns of Care (POC) studies performed by
the SEER registries which involve obtaining more detailed
information about CT and HT verified by the treating
physician. These individuals were excluded as we were in-
terested in the routine collection of SEER data (n = 2671).18
Identification of Treatment
Treatment information was identified independently
from the SEER data and from Medicare claims. SEER col-
lects information on the first course of therapy. As in-
dividuals initiate therapy at different times postdiagnosis,
cancer registrars update treatment information as it becomes
available. For analysis, SEER treatment data for CT, RT, and
HT were classified as received, not received, or unknown.
Treatment information for CT, RT, and HT was
identified from Medicare claims data by reviewing the
MEDPAR, outpatient, physician, and DME claims for 12
months after diagnosis. The first of the month and year of
diagnosis reported by SEER registries was used as the di-
agnosis date. An individual was considered to have received
CT, RT, or HT if at least 1 Medicare claim included a code
for each specific treatment and to not have received treat-
ment if no claims for the specific treatments were found.
Thus, no individual had an unknown treatment status from
the Medicare data. Codes used to identify treatment are listed
in Table (Supplemental Digital Content 1, http://links.lww.
com/MLR/A665, which lists codes).
Comparison of SEER and Medicare Treatment
Data
Sensitivity, specificity, PPV, and NPV and their 95%
confidence intervals were calculated to quantify the validity
of SEER data to identify treatment receipt using Medicare
claims as the gold standard. Although we calculated sensi-
tivity, specificity, PPV, and NPV, we focused our analyses
on sensitivity and PPV with the other measures reported in
the Supplemental Tables (Supplemental Digital Content
2–4, http://links.lww.com/MLR/A666, http://links.lww.com/
MLR/A667, http://links.lww.com/MLR/A668, which shows
additional statistics).19 The analysis was performed sepa-
rately for each treatment and by patient characteristics such
as cancer site, stage, sex, age, race/ethnicity, geographic
location, and year of diagnosis from the SEER data. As
SEER does not define a fixed interval for the collection of
treatment information, the overall sensitivity and PPV were
also evaluated using a 4- and 8-month postdiagnosis Medi-
care claims window to provide a comparison to the 12-month
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claims window length. Concordance between the 2 data
sources was quantified with the k statistic and the percent
agreement which was defined as the proportion of in-
dividuals with the same reported treatment receipt from
SEER and Medicare data (ie, the number of individuals
where SEER data and Medicare claims agree about treatment
receipt/total number of individuals with treatment recorded
in SEER). Neither of these quantities assumes a gold
standard but the k statistic does account for agreement
occurring by chance alone.
RESULTS
Our analysis included a total of 433,415 individuals
diagnosed with the selected cancers. Twenty-seven percent
of individuals were diagnosed with prostate cancer followed
by lung (24%), female breast (18%), and colorectal (18%)
(Table 1). The remaining individuals were diagnosed with
bladder, pancreatic, or ovarian cancer (7%, 5%, and 2%,
respectively). The majority of individuals were diagnosed at
localized or regional stage except for individuals with cancer
of the lung, pancreas, or ovary who were primarily diagnosed
with distant stage disease. Our study included individuals
who were predominantly non-Hispanic whites (82%) and
diagnosed at ages 65–79 years.
CT
A total of 415,341 individuals were included in the
comparison of CT after excluding 4.2% with unknown CT
status from SEER. For all cancers combined, there was a
high level of agreement between the Medicare claims and the
SEER data (90%, Fig. 1), attributable to the fact that most
individuals did not receive CT. The majority of discordant
findings were individuals identified as receiving CT using
Medicare claims but not receiving CT using SEER data.
The sensitivity of SEER data to identify individuals
who received CT was 68% overall and varied by patient and
tumor characteristics (Table 2). The sensitivity of SEER data
was highest for ovarian cancer and lowest for bladder and
prostate cancers (84%, 22%, and 7%, respectively). In ad-
dition, the sensitivity decreased with age for all cancers
combined, specifically 74% for individuals aged 65–69
compared with 47% for those aged 85 and older. The sen-
sitivity was low for detecting CT in individuals diagnosed
with in situ or localized disease. In addition, there was some
variation in sensitivity by registry (range, 60%–78%). The
sensitivity, however, did not vary greatly based on year of
diagnosis (data not shown), sex, or race with the exception of
individuals with unknown race.
The poor results for prostate cancer did not, however,
greatly affect the overall results because so few men receive
CT as first-course therapy. Specifically, among men with all
cancer sites combined, the sensitivity was 62.3% and mod-
estly increased to 66.3% when prostate cancer was excluded.
Finally, we further investigated potential misclassification of
men with prostate cancer who had a claim for CT admin-
istration that may have been used for delivery of HT. We
considered additional CT administration claims found on the
same day as HT but the number of men with these additional
codes was small and hence their impact on the overall results
would be minimal.
Overall the PPV was high indicating that among those
identified in the SEER data as receiving CT, the vast ma-
jority also had Medicare claims for CT (Table 2). The k
statistics showed a moderate level of agreement overall and
also followed a similar pattern to sensitivity and PPV. The
specificity (range, 93%–100%) and NPV (range, 80%–99%
excluding bladder) were high across all characteristics
(Table, Supplemental Digital Content 2, http://links.lww.
com/MLR/A666, which shows additional statistics for CT).
Finally, as an addition to the sensitivity analysis we eval-
uated the individuals excluded because of unknown CT
in SEER data and found them to have similar rate of CT as
those with known CT status (72% vs. 76%, respectively).
RT
Overall 2.8% of individuals had unknown RT status
reported in the SEER data, thus 412,350 patients were
available for comparison. The overall agreement between
Medicare claims and the SEER data for identifying RT was
high (91%, Fig. 1). The majority of discordant findings were
individuals identified as receiving RT using Medicare claims
but were not identified using SEER data (7.4%).
The sensitivity of SEER data to identify individuals
who received RT was 80% overall and varied by patient and
tumor characteristics (Table 3). The sensitivity of SEER data
was highest for prostate cancer (85%), lowest for bladder
(54%), and ranged between 66% and 80% for the remaining
cancer sites. The sensitivity decreased by year of diagnosis
(data not shown, range, 82%–78%) and increasing age
(range, 81%–65%). The sensitivity did not vary greatly by
stage or race with the exception of low sensitivity of in-
dividuals in the unstaged or unknown race categories.
For all cancer sites combined, the PPV of RT on the
SEER data was 95%. Although there was some variation in
PPV by patient and tumor characteristics, the PPV was high
for all cancer sites. The overall k statistics were moderate to
strong and followed a similar pattern as sensitivity and PPV.
In addition, the overall specificity and NPV were high. The
specificity overall was 97% and ranged between 94% and
100% by characteristic and the NPV was 89% overall and
ranged from 82% to 96% (Table, Supplemental Digital
Content 3, http://links.lww.com/MLR/A667, which shows
additional statistics for RT). For all cancer sites combined,
73% of those with unknown RT in the SEER data did not
have claims, ranging from 90% for colorectal cancer to 60%
for breast cancer.
HT
A total of 115,724 men with prostate cancer were in
the study cohort and 111,466 had known HT status recorded
in the SEER data and were included in the analysis of HT.
The overall agreement between SEER and Medicare was
81% (Fig. 1).
The sensitivity of the SEER data to identify HT was
69% and followed a similar pattern to CT. Specifically, the
sensitivity was lower for localized/regional stage or un-
known stage disease and decreased with increasing age
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TABLE 1. Characteristics of 433,415 Individuals Diagnosed With Selected Cancers and Included in Analysis by Cancer Site
N (%)
Bladder Female Breast Colorectal Lung Ovary Pancreas Prostate
N=29,259 (6.8%) N=78,609 (18.1%) N=77,242 (17.8%) N=103,640 (23.9%) N=8920 (2.1%) N=20,021 (4.6%) N=115,724 (26.7%)
Stage at diagnosis*
In situ 0 (0) 11,901 (15.1) 3890 (5.0) 54 (0.1) 16 (0.2) 49 (0.2) 23 (0.02)
Localized 21,339 (72.9) 42,548 (54.1) 29,486 (38.2) 17,129 (16.5) 815 (9.1) 1740 (8.7) —
Regional 5768 (19.7) 17,389 (22.1) 25,279 (32.7) 24,774 (23.9) 542 (6.1) 4963 (24.8) —
Localized/regionalw 105,132 (90.8)
Distant 1134 (3.9) 4832 (6.1) 14,047 (18.2) 53,442 (51.6) 6612 (74.1) 10,086 (50.4) 5710 (4.9)
Unstaged 1018 (3.5) 1939 (2.5) 4540 (5.9) 8241 (8.0) 935 (10.5) 3183 (15.9) 4859 (4.2)
Sex
Male 20,867 (71.3) — 34,417 (44.6) 54,016 (52.1) — 8605 (43.0) 115,724 (100)
Female 8392 (28.7) 78,609 (100) 42,825 (55.4) 49,624 (47.9) 8920 (100) 11,416 (57.0) —
Age at diagnosis (y)
65–69 5123 (17.5) 19,488 (24.8) 14,105 (18.3) 23,078 (22.3) 1784 (20.0) 3564 (17.8) 33,991 (29.4)
70–74 6317 (21.6) 18,417 (23.4) 15,739 (20.4) 26,271 (25.3) 1881 (21.1) 4260 (21.3) 32,720 (28.3)
75–79 6840 (23.4) 17,844 (22.7) 17,098 (22.1) 25,642 (24.7) 2010 (22.5) 4628 (23.1) 26,111 (22.6)
80–84 5810 (19.9) 12,988 (16.5) 15,336 (19.9) 17,593 (17.0) 1726 (19.3) 3913 (19.5) 14,681 (12.7)
85+ 5169 (17.7) 9872 (12.6) 14,964 (19.4) 11,056 (10.7) 1519 (17.0) 3656 (18.3) 8221 (7.1)
Race/ethnicity
NH white 25,955 (88.7) 66,530 (84.6) 62,922 (81.5) 86,889 (83.8) 7569 (84.9) 15,816 (79.0) 89,213 (77.1)
NH black 1171 (4.0) 5489 (7.0) 6329 (8.2) 8371 (8.1) 537 (6.0) 1936 (9.7) 11,536 (10.0)
Hispanic 1011 (3.5) 3414 (4.3) 3972 (5.1) 3985 (3.8) 494 (5.5) 1209 (6.0) 7100 (6.1)
NH AI/AN 29 (0.1) 170 (0.2) 163 (0.2) 289 (0.3) 37 (0.4) 73 (0.4) 266 (0.2)
NH API 730 (2.5) 2609 (3.3) 3483 (4.5) 3959 (3.8) 268 (3.0) 964 (4.8) 4296 (3.7)
NH other/unknown 363 (1.2) 397 (0.5) 373 (0.5) 147 (0.1) 15 (0.2) 23 (0.1) 3313 (2.9)
Year of diagnosis
2000 3754 (12.8) 10,625 (13.5) 11,015 (14.3) 13,957 (13.5) 1367 (15.3) 2607 (13.0) 15,626 (13.5)
2001 3894 (13.3) 11,596 (14.8) 11,337 (14.7) 14,460 (14.0) 1310 (14.7) 2701 (13.5) 16,711 (14.4)
2002 4116 (14.1) 11,707 (14.9) 11,729 (15.2) 15,034 (14.5) 1118 (12.5) 2916 (14.6) 17,814 (15.4)
2003 3949 (13.5) 11,421 (14.5) 11,608 (15.0) 15,648 (15.1) 1310 (14.7) 2966 (14.8) 16,731 (14.5)
2004 4677 (16.0) 11,085 (14.1) 11,232 (14.5) 15,412 (14.9) 1289 (14.5) 2967 (14.8) 16,835 (14.5)
2005 4424 (15.1) 11,050 (14.1) 10,152 (13.1) 14,436 (13.9) 1229 (13.8) 2822 (14.1) 15,566 (13.5)
2006 4445 (15.2) 11,125 (14.2) 10,169 (13.2) 14,693 (14.2) 1297 (14.5) 3042 (15.2) 16,441 (14.2)
Reporting sourcez
Inpatient 27,795 (95.0) 76,584 (97.4) 74,907 (97.0) 98,951 (95.5) 8555 (95.9) 18,487 (92.3) 94,636 (81.8)
RT or Med Onc Center — 51 (0.1) — 48 (0.0) — — 299 (0.3)
Laboratory only 545 (1.9) 607 (0.8) 600 (0.8) 312 (0.3) 27 (0.3) 56 (0.3) 8085 (7.0)
Physician’s office 812 (2.8) 1188 (1.5) 1603 (2.1) 3967 (3.8) 295 (3.3) 1341 (6.7) 12,426 (10.7)
Nursing 17 (0.1) 62 (0.1) 93 (0.1) 285 (0.3) 39 (0.4) 111 (0.6 89 (0.1)
Other 83 (0.3) 117 (0.1) 27 (0.0) 77 (0.1) — 18 (0.1) 189 (0.2)
*SEER historic stage A.
wProstate cancer is categorized as in situ, localized/regional, or distant. All other cancer sites have localized and regional as separate categories.
zReporting source is from the Medicare data. Inpatient, hospital inpatient; RT or Med Onc Center, Radiation Treatment Centers or Medical Oncology Centers; Physician’s office, Physician’s Office/Private Medical Practitioner;
Nursing, Nursing/Convalescent/Hospice; Other, Other Hospital Outpatient Units/Surgery Centers.
— indicates cell counts were suppressed if <16 individuals; AI/AN, American Indian/Alaskan Native; API, Asian/Pacific Islander; NH, non-Hispanic.
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(Table 4). The sensitivity did not vary much by race with the
exception of unknown race and, finally, the sensitivity varied
by registry (range, 47%–76%).
The overall PPV was 86% and did not vary substantially
by characteristic. American Indian/Alaska Natives and those
with distant-stage disease had lower PPVs (66% and 75%,
respectively). The overall k showed a low level of agreement.
Similar to CT and RT, the specificity was high except for
distant stage; however, the NPV was only 78% overall (Table,
Supplemental Digital Content 4, http://links.lww.com/MLR/
A668, which shows additional statistics for HT). The NPV was
lower for individuals with distant (61%) or unstaged (66%)
cancers compared with local/regional stage (79%) or for older
patients (87% for age 65–69 vs. 62% for age 85+). The NPV
did not vary substantially by race or registry.
DISCUSSION
In order for the treatment data recorded by the SEER
registries to be useful to assess how patients are treated, the
information must have good sensitivity and PPV. We found
that the overall utility of the SEER data to identify cancer
treatment was limited. The sensitivity of the SEER data
varied by treatment type, cancer site, stage, age at diagnosis,
and registry. For CT and HT, the sensitivity was low,
whereas the sensitivity was better for reporting of RT. We
investigated whether SEER data may be appropriate for use
among specific site/stage strata. However, for the cancer sites
included in this analysis the sensitivity was <90% for all
stages and treatment types (See Table, Supplemental Digital
Content 5, http://links.lww.com/MLR/A672 which shows
sensitivity and PPV by cancer site and stage). These results
indicate that using SEER data to assess treatment will miss a
number of patients who have been treated, resulting in
misclassification and inaccurate estimates of the proportion
of individuals treated.
Although the sensitivity was poor, the PPV was high
among all treatment types and did not vary greatly by cancer
site or characteristic with the exception of CT for prostate
cancer. As within many site/stage strata SEER reliably
identified individuals who truly received treatment, SEER
treatment data may have a limited role in research projects to
identify a cohort of treated individuals within these strata
(See Table, Supplemental Digital Content 5, http://links.
lww.com/MLR/A672 which shows sensitivity and PPV by
cancer site and stage). SEER data, however, will not capture
all individuals who received treatment.
This is the first study to compare CT reported in the
SEER data with Medicare claims. Prior studies from 2 SEER
registries compared CT data collected by medical records to
registry data for women of all ages with breast cancer. These
earlier studies had similar rates of concordance as the current
study.7,20 As treatment is more often received in settings
outside of the hospital system, either a physician’s office or
an outpatient clinic, identification of treatment is difficult and
may be a major contributing factor to the low capture of CT
50.3%
62.1%
74.2%
30.8%
28.8%
16.3%
13.9%
7.4%
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FIGURE 1. Agreement between chemotherapy, radiation, and hormone therapy collected by SEER and treatment identified using
Medicare claimsa. aA 12-month postdiagnosis window was used to identify treatment using Medicare claims (gold standard).
SEER indicates Surveillance, Epidemiology, and End Results.
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TABLE 2. Sensitivity and PPV of SEER Data to Identify Chemotherapy Receipt and k Statistics by Patient and Tumor
Characteristics*
SEER No,
Medicare No
SEER Yes,
Medicare Yes
SEER No,
Medicare Yes
SEER Yes,
Medicare No
Sensitivity
(95% CI)w
PPV
(95% CI)w
j
(95% CI)
Overall
12mo window 308,119 67,681 32,184 7357 67.8 (67.5, 68.1) 90.2 (90.0, 90.4) 71.5 (71.3, 71.8)
8mo window 310,664 67,234 29,639 7804 69.4 (69.1, 69.7) 89.6 (89.4, 89.8) 72.7 (72.4, 72.9)
4mo window 314,771 65,103 25,532 9935 71.8 (71.5, 72.1) 86.8 (86.5, 87.0) 73.3 (73.1, 73.6)
Cancer site
Bladder 16,760 2468 8,848 293 21.8 (21.0, 22.6) 89.4 (88.2, 90.5) 23.0 (22.1, 23.9)
Female Breast 58,972 10,330 4726 996 68.6 (67.9, 69.4) 91.2 (90.7, 91.7) 73.8 (73.2, 74.4)
Colorectal 50,646 14,909 5967 1413 71.4 (70.8, 72.0) 91.3 (90.9, 91.8) 73.5 (72.9, 74.1)
Lung 57,068 30,030 7446 3562 80.1 (79.7, 80.5) 89.4 (89.1, 89.7) 75.8 (75.3, 76.2)
Ovary 3109 4285 790 239 84.4 (83.4, 85.4) 94.7 (94.1, 95.4) 75.2 (73.8, 76.6)
Pancreas 11,402 5442 1608 522 77.2 (76.2, 78.2) 91.2 (90.5, 92.0) 75.2 (74.2, 76.2)
Prostate 110,162 217 2799 332 7.2 (6.3, 8.1) 39.5 (35.4, 43.6) 11.4 (10.0, 12.9)
Stage at diagnosisz
In situ 15,137 26 218 49 10.7 (6.8, 14.5) 34.7 (23.9, 45.4) 15.7 (10.2, 21.2)
Localized 86,334 8915 12,271 1165 42.1 (41.4, 42.7) 88.4 (87.8, 89.1) 50.8 (50.2, 51.5)
Localized/
regionaly
101,176 105 2029 242 4.9 (4.0, 5.8) 30.3 (25.4, 35.1) 7.9 (6.4, 9.4)
Regional 37,467 26,267 8492 2118 75.6 (75.1, 76.0) 92.5 (92.2, 92.8) 71.0 (70.5, 71.5)
Distant 49,518 30,743 7704 3535 80.0 (79.6, 80.4) 89.7 (89.4, 90.0) 74.4 (74.0, 74.9)
Unstaged 18,487 1625 1470 248 52.5 (50.7, 54.3) 86.8 (85.2, 88.3) 61.3 (59.6, 62.9)
Sex
Female 131,627 39,592 15,190 3404 72.3 (71.9, 72.6) 92.1 (91.8, 92.3) 74.5 (74.2, 74.9)
Male 176,492 28,089 16,994 3953 62.3 (61.9, 62.8) 87.7 (87.3, 88.0) 67.4 (67.0, 67.8)
Age at diagnosis (y)
65–69 65,372 21,811 7874 2153 73.5 (73.0, 74.0) 91.0 (90.7, 91.4) 74.3 (73.8, 74.8)
70–74 70,775 20,113 8521 1906 70.2 (69.7, 70.8) 91.3 (91.0, 91.7) 72.7 (72.2, 73.2)
75–79 70,378 15,836 7937 1661 66.6 (66.0, 67.2) 90.5 (90.1, 90.9) 70.5 (70.0, 71.1)
80–84 55,058 7569 5190 1062 59.3 (58.5, 60.2) 87.7 (87.0, 88.4) 65.6 (64.9, 66.4)
85+ 46,536 2352 2662 575 46.9 (45.5, 48.3) 80.4 (78.9, 81.8) 56.1 (54.8, 57.5)
Race/ethnicity
NH white 250,536 56,576 26,730 5710 67.9 (67.6, 68.2) 90.8 (90.6, 91.1) 71.8 (71.5, 72.1)
NH black 25,896 4,881 2215 826 68.8 (67.7, 69.9) 85.5 (84.6, 86.4) 70.8 (69.8, 71.8)
Hispanic 15,281 3225 1620 405 66.6 (65.2, 67.9) 88.8 (87.8, 89.9) 70.1 (68.8, 71.3)
NH AI/AN 747 188 58 19 76.4 (71.1, 81.7) 90.8 (86.9, 94.8) 78.1 (73.5, 82.8)
NH API 11,510 2736 1307 379 67.7 (66.2, 69.1) 87.8 (86.7, 89.0) 69.8 (68.4, 71.1)
NH other/
unknown
4149 75 254 18 22.8 (18.3, 27.3) 80.6 (72.6, 88.7) 33.4 (27.6, 39.2)
Registry8
A 78.2 (77.3, 79.1) 90.9 (90.3, 91.6) 78.4 (77.6, 79.2)
B 65.6 (64.5, 66.7) 90.1 (89.4, 90.9) 70.0 (69.0, 70.9)
C 78.6 (77.7, 79.6) 92.5 (91.8, 93.2) 80.9 (80.1, 81.7)
D 62.8 (60.8, 64.9) 88.8 (87.2, 90.4) 67.9 (66.1, 69.8)
E 65.5 (64.4, 66.5) 91.8 (91.1, 92.5) 70.4 (69.4, 71.4)
F 70.8 (69.8, 71.8) 88.8 (88.0, 89.6) 73.3 (72.4, 74.2)
G 64.7 (64.2, 65.2) 88.3 (87.9, 88.7) 68.5 (68.0, 69.0)
H 62.8 (62.1, 63.5) 92.2 (91.7, 92.6) 67.8 (67.1, 68.5)
I 66.0 (64.4, 67.6) 91.6 (90.5, 92.7) 70.3 (68.9, 71.8)
J 60.1 (58.0, 62.3) 91.6 (90.1, 93.1) 68.0 (66.1, 70.0)
K 77.7 (76.6, 78.8) 89.7 (88.8, 90.6) 78.9 (77.9, 79.9)
L 70.8 (68.4, 73.3) 88.4 (86.4, 90.3) 73.2 (71.0, 75.4)
*A 12-month postdiagnosis window was used to identify treatment using Medicare claims (gold standard) unless otherwise specified.
w95% CIs computed using normal approximation.
zSEER historic stage A.
yProstate cancer is categorized as in situ, localized/regional, or distant. All other cancer sites have localized and regional as separate categories.
8Sample sizes omitted to preserve anonymity of the registries. Data from registries in California were combined (Greater California, Los Angeles, and San Jose-Monterey) and
data from registries in Georgia were combined (Atlanta and Rural Georgia).
AI/AN indicates American Indian/Alaskan Native; API, Asian/Pacific Islander; CI, confidence interval; NH, non-Hispanic; PPV, positive predictive value; SEER, Surveillance,
Epidemiology, and End Results.
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in the SEER data. For example, the low sensitivity of CT for
bladder cancer is likely explained by more patients being
treated primarily in the physician office. Other challenges
include a trend away from intravenous CT drugs to oral CT
and identification of prescription drug use is difficult for
cancer registrars to find.
Among men with prostate cancer, the sensitivity of
CT was poor, even among men with distant-stage disease
TABLE 3. Sensitivity and PPV of SEER Data to Identify Radiation Therapy and k Statistics by Patient and Tumor Characteristics*
SEER No,
Medicare No
SEER Yes,
Medicare Yes
SEER No,
Medicare Yes
SEER Yes,
Medicare No
Sensitivity
(95% CI)w
PPV
(95% CI)w j (95% CI)
Overall
12mo window 256,031 118,949 30,529 6841 79.6 (79.4, 79.8) 94.6 (94.4, 94.7) 79.7 (79.5, 79.9)
8mo window 260,499 116,358 26,061 9432 81.7 (81.5, 81.9) 92.5 (92.4, 92.6) 80.4 (80.2, 80.6)
4mo window 267,798 101,995 18,762 23,795 84.5 (84.3, 84.7) 81.1 (80.9, 81.3) 75.4 (75.2, 75.6)
Cancer site
Bladder 25,809 1492 1283 106 53.8 (51.9, 55.6) 93.4 (92.1, 94.6) 65.8 (64.2, 67.5)
Female breast 36,076 31,232 8026 808 79.6 (79.2, 80.0) 97.5 (97.3, 97.6) 76.9 (76.5, 77.4)
Colorectal 65,932 5962 3036 393 66.3 (65.3, 67.2) 93.8 (93.2, 94.4) 75.2 (74.4, 76.0)
Lung 56,114 32,666 9396 2039 77.7 (77.3, 78.1) 94.1 (93.9, 94.4) 76.0 (75.6, 76.4)
Pancreas 15,897 2447 1042 100 70.1 (68.6, 71.7) 96.1 (95.3, 96.8) 77.7 (76.5, 78.9)
Prostate 56,203 45,150 7746 3395 85.4 (85.1, 85.7) 93.0 (92.8, 93.2) 80.0 (79.7, 80.4)
Stage at diagnosisz
In situ 9945 4451 1039 103 81.1 (80.0, 82.1) 97.7 (97.3, 98.2) 83.3 (82.3, 84.2)
Localized 77,219 24,449 6975 824 77.8 (77.3, 78.3) 96.7 (96.5, 97.0) 81.5 (81.1, 81.9)
Localized/
regionaly
48,928 43,733 6648 3174 86.8 (86.5, 87.1) 93.2 (93.0, 93.5) 80.8 (80.4, 81.2)
Regional 45,632 22,272 6901 1148 76.3 (75.9, 76.8) 95.1 (94.8, 95.4) 76.7 (76.3, 77.2)
Distant 56,203 22,364 7177 1397 75.7 (75.2, 76.2) 94.1 (93.8, 94.4) 77.0 (76.5, 77.4)
Unstaged 18,104 1680 1789 195 48.4 (46.8, 50.1) 89.6 (88.2, 91.0) 58.2 (56.6, 59.8)
Sex
Female 117,289 51,088 15,423 1441 76.8 (76.5, 77.1) 97.3 (97.1, 97.4) 79.3 (79.0, 79.6)
Male 138,742 67,861 15,106 5400 81.8 (81.5, 82.1) 92.6 (92.4, 92.8) 80.0 (79.8, 80.3)
Age at diagnosis (y)
65–69 51,784 34,082 7957 2599 81.1 (80.7, 81.4) 92.9 (92.7, 93.2) 77.4 (77.0, 77.8)
70–74 54,250 36,246 8120 2091 81.7 (81.3, 82.1) 94.5 (94.3, 94.8) 79.1 (78.8, 79.5)
75–79 57,258 29,372 7368 1383 79.9 (79.5, 80.4) 95.5 (95.3, 95.7) 80.0 (79.6, 80.4)
80–84 49,431 14,035 4304 575 76.5 (75.9, 77.1) 96.1 (95.7, 96.4) 80.6 (80.1, 81.1)
85+ 43,308 5214 2780 193 65.2 (64.2, 66.3) 96.4 (95.9, 96.9) 74.6 (73.8, 75.5)
Race/ethnicity
NH white 208,152 98,707 24,742 5066 80.0 (79.7, 80.2) 95.1 (95.0, 95.2) 80.3 (80.1, 80.5)
NH black 20,913 9410 2598 1052 78.4 (77.6, 79.1) 89.9 (89.4, 90.5) 75.8 (75.1, 76.5)
Hispanic 12,988 5465 1528 385 78.1 (77.2, 79.1) 93.4 (92.8, 94.1) 78.3 (77.4, 79.2)
NH AI/AN 630 250 70 22 78.1 (73.6, 82.7) 91.9 (88.7, 95.2) 77.7 (73.4, 82.0)
NH API 9907 4585 1092 282 80.8 (79.7, 81.8) 94.2 (93.5, 94.9) 80.5 (79.6, 81.5)
NH other/
unknown
3441 532 499 34 51.6 (48.5, 54.7) 94.0 (92.0, 96.0) 60.2 (57.2, 63.1)
Registry8
A 82.6 (81.9, 83.2) 93.4 (92.9, 93.9) 80.4 (79.7, 81.1)
B 74.0 (73.2, 74.8) 95.9 (95.5, 96.3) 75.5 (74.7, 76.2)
C 85.9 (85.2, 86.6) 96.0 (95.6, 96.5) 86.7 (86.0, 87.3)
D 68.4 (66.8, 70.0) 93.7 (92.7, 94.7) 71.0 (69.5, 72.5)
E 72.8 (72.0, 73.6) 95.4 (95.0, 95.9) 73.0 (72.2, 73.7)
F 82.9 (82.3, 83.6) 95.3 (94.9, 95.6) 82.3 (81.7, 83.0)
G 79.2 (78.8, 79.6) 94.0 (93.7, 94.2) 79.7 (79.4, 80.1)
H 78.6 (78.1, 79.1) 95.2 (94.9, 95.5) 78.9 (78.5, 79.4)
I 82.2 (81.1, 83.2) 94.9 (94.2, 95.5) 81.2 (80.2, 82.3)
J 82.5 (81.3, 83.8) 95.4 (94.7, 96.2) 83.3 (82.2, 84.4)
K 86.9 (86.2, 87.7) 92.1 (91.5, 92.7) 83.8 (83.1, 84.5)
L 82.6 (81.1, 84.2) 93.2 (92.1, 94.3) 79.5 (77.9, 81.1)
*A 12-month postdiagnosis window was used to identify treatment using Medicare claims (gold standard) unless otherwise specified.
w95% CIs computed using normal approximation.
zSEER historic stage A.
yProstate cancer is categorized as in situ, localized/regional, or distant. All other cancer sites have localized and regional as separate categories.
8Sample sizes omitted to preserve anonymity of the registries. Data from registries in California were combined (Greater California, Los Angeles, and San Jose-Monterey) and
data from registries in Georgia were combined (Atlanta and Rural Georgia).
AI/AN indicates American Indian/Alaskan Native; API, Asian/Pacific Islander; CI, confidence interval; NH, non-Hispanic; PPV, positive predictive value; SEER, Surveillance,
Epidemiology, and End Results.
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(13.6% vs. 4.9% for localized/regional stage). These find-
ings could be influenced by the challenges of distinguish-
ing men who received CT, HT, or both using Medicare
claims. Among men with prostate cancer included in this
analysis who received CT according to Medicare claims,
67% also had a claim for HT within the same year. For
these men, we cannot definitively determine if all claims
were related to administration of HT or if some were for
CT. A recent study compared CT and HT data compiled by
the Cancer Research Network’s (CRN) Virtual Data Ware-
house, which included encounter, claims, and electronic
medical record data, to gold standard tumor registry data
abstracted from medical charts.21 The PPV for identifying CT
for prostate cancer was only 6%, similar to our current
findings. These results reflect the fact that registry data is
limited to the first course of therapy and the difficulty in
distinguishing CT and HT using claims for prostate cancer. In
contrast to poor reporting of CT in the CRN data, the authors
found that among men with prostate cancer identified as
receiving HT in the CRN data, 92% also had HT captured in
the tumor registry data. The success in identifying HT from
the CRN claims data compared with Medicare claims may
be due to availability of pharmacy information in the CRN
data.
We found moderate sensitivity and agreement between
SEER data and Medicare claims for receipt of RT. In pre-
TABLE 4. Sensitivity and PPV of the SEER Data to Identify Hormone Therapy and k Statistics by Patient and Tumor Characteristics
Among Men With Prostate Cancer*
SEER No,
Medicare No
SEER Yes,
Medicare Yes
SEER No,
Medicare Yes
SEER Yes,
Medicare No
Sensitivity
(95% CI)w
PPV
(95% CI)w
j
(95% CI)
Overall
12mo window 56,022 34,379 15,451 5614 69.0 (68.6, 69.4) 86.0 (85.6, 86.3) 61.0 (60.6, 61.5)
8mo window 56,723 33,955 14,750 6038 69.7 (69.3, 70.1) 84.9 (84.6, 85.3) 61.3 (60.8, 61.8)
4mo window 57,867 32,516 13,606 7477 70.5 (70.1, 70.9) 81.3 (80.9, 81.7) 60.2 (59.8, 60.7)
Stage at diagnosisz
In situ — — — — — — —
Localized/
regional
52,831 30,748 13,673 4470 69.2 (68.8, 69.6) 87.3 (87.0, 87.7) 62.9 (62.4, 63.4)
Distant 1104 2796 720 937 79.5 (78.2, 80.9) 74.9 (73.5, 76.3) 34.4 (31.8, 36.9)
Unstaged 2073 827 1058 207 43.9 (41.6, 46.1) 80.0 (77.5, 82.4) 36.2 (33.6, 38.8)
Age at diagnosis (y)
65–69 20,780 7566 3090 1499 71.0 (70.1, 71.9) 83.5 (82.7, 84.2) 66.9 (66.0, 67.8)
70–74 16,401 9943 3719 1542 72.8 (72.0, 73.5) 86.6 (86.0, 87.2) 65.4 (64.6, 66.3)
75–79 10,703 9126 4033 1283 69.4 (68.6, 70.1) 87.7 (87.0, 88.3) 58.1 (57.1, 59.0)
80–84 5209 5147 2838 808 64.5 (63.4, 65.5) 86.4 (85.6, 87.3) 49.0 (47.6, 50.4)
85+ 2929 2597 1771 482 59.5 (58.0, 60.9) 84.3 (83.1, 85.6) 43.5 (41.7, 45.4)
Race/ethnicity
NH white 44,009 26,430 11,397 3899 69.9 (69.4, 70.3) 87.1 (86.8, 87.5) 63.1 (62.5, 63.6)
NH black 5333 3361 1496 937 69.2 (67.9, 70.5) 78.2 (77.0, 79.4) 55.0 (53.4, 56.5)
Hispanic 3166 2187 1160 436 65.3 (63.7, 67.0) 83.4 (82.0, 84.8) 53.7 (51.7, 55.6)
NH AI/AN 131 66 31 34 68.0 (58.8, 77.3) 66.0 (56.7, 75.3) 47.1 (36.1, 58.1)
NH API 1856 1523 607 220 71.5 (69.6, 73.4) 87.4 (85.8, 88.9) 60.8 (58.4, 63.1)
NH other/
unknown
1527 812 760 88 51.7 (49.2, 54.1) 90.2 (88.3, 92.2) 46.5 (43.7, 49.3)
Registryy
A 72.4 (70.7, 74.0) 82.8 (81.3, 84.2) 59.9 (57.9, 61.8)
B 70.8 (69.4, 72.1) 87.5 (86.4, 88.6) 60.7 (59.0, 62.3)
C 71.6 (70.1, 73.2) 89.5 (88.4, 90.7) 64.5 (62.8, 66.3)
D 47.4 (44.4, 50.4) 72.7 (69.4, 76.0) 42.4 (39.1, 45.8)
E 67.0 (65.4, 68.6) 84.5 (83.1, 85.8) 55.4 (53.5, 57.3)
F 60.9 (59.4, 62.5) 86.9 (85.6, 88.2) 57.8 (56.2, 59.5)
G 70.6 (69.9, 71.4) 84.8 (84.2, 85.5) 63.0 (62.1, 63.8)
H 70.2 (69.3, 71.1) 87.9 (87.2, 88.6) 55.2 (54.0, 56.4)
I 50.9 (48.0, 53.9) 81.1 (78.1, 84.0) 51.4 (48.3, 54.5)
J 70.8 (68.5, 73.1) 88.3 (86.5, 90.1) 68.9 (66.6, 71.2)
K 72.9 (71.2, 74.7) 87.0 (85.5, 88.5) 69.8 (68.0, 71.6)
L 75.6 (72.8, 78.4) 86.8 (84.4, 89.2) 61.3 (57.5, 65.0)
*A 12-month postdiagnosis window was used to identify treatment using Medicare claims (gold standard) unless otherwise specified.
w95% CIs computed using normal approximation.
zSEER historic stage A.
ySample sizes omitted to preserve anonymity of the registries. Data from registries in California were combined (Greater California, Los Angeles, and San Jose-Monterey) and
data from registries in Georgia were combined (Atlanta and Rural Georgia).
— indicates cell counts were suppressed if <16 individuals and statistics were not calculated due to at least 1 cell size <5; AI/AN, American Indian/Alaskan Native; API, Asian/
Pacific Islander; CI, confidence interval; NH, non-Hispanic; PPV, positive predictive value; SEER, Surveillance, Epidemiology, and End Results.
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vious comparisons of reported RT use between SEER
and Medicare data, breast, endometrial, lung, prostate, and
rectal cancer had strong agreement when comparing RT use
for individuals diagnosed between 1991 and 1996.4 A more
recent study compared receipt of RT as reported in the
SEER data for individuals diagnosed with breast cancer aged
20 to 79 and diagnosed between 2005 and 2007 with self-
reported treatment information obtained through patient
survey.2 This analysis found overall agreement of 83%,
and 21% of individuals who self-reported receiving RT were
recorded as not receiving RT in the SEER data. Under-
ascertainment of RT was higher in women under the age
of 65 who would not be eligible for Medicare. We also found
more underreporting of RT in the SEER data, about
21%, which is consistent with the more recent study.1,2,5
The poorer performance with more recent diagnoses could be
due to the increasing difficulty for registries to collect
treatment information delivered in the outpatient setting.
Underascertainment of RT may also result if individuals
receive surgical treatment in a large cancer center but receive
RT in a community setting.
There are several limitations to this study. One caveat
is the potential for underreporting of treatment by both
Medicare claims and the SEER data. Underreporting
of treatment in the Medicare claims would result from
individuals receiving care outside of the Medicare system,
such as from the Veterans Health Administration, or if in-
dividuals are still working and have employer-sponsored
insurance. Whereas, underreporting of treatment in the SEER
data may be caused by care not captured by the registry, such
as prescription drugs or outpatient treatment, or individuals
leaving the registry catchment area for treatment. The
sensitivity among those over the age of 85 is lower which
may be due to these individuals leaving home while re-
ceiving treatment. In addition, the sensitivity varied by reg-
istry. This may be due to differences in how the data are
collected at the registry and the proportion of patients re-
ceiving inpatient treatment.
Apparent differences in the reporting of treatment between
the SEER and Medicare data may be caused by misalignment of
the treatment window captured by SEER and Medicare files. In
this evaluation, a 12-month postdiagnosis window was used to
identify claims from Medicare. This timeframe was chosen as it
aligned with guidelines from the SEER Program Coding and
Staging Manual followed by SEER registrars stating that in the
absence of additional documentation the first course of therapy
ends after 1 year postdiagnosis.22 However, SEER is only cap-
turing first-course treatment, whereas Medicare claims would
also capture secondary treatment due to an inability of
individuals to tolerate the initial treatment or failure of the initial
treatment to produce the desired outcome. The overall sensitivity
of the SEER data increased and the PPV decreased using a
shorter window postdiagnosis to identify claims but these dif-
ferences were modest (Tables 2–4).
In addition, there may have been some missed oppor-
tunity for the SEER registries to capture treatment. We re-
viewed the claims for individuals identified as having received
treatment in Medicare but not in the SEER data to determine
the number of encounters the individual had with the health
care system. The number of encounters was quantified by the
number of days in the first year postdiagnosis a claim for
treatment was found. Thirty-two percent of individuals with
any claims for CT and 55% of those with any claims for RT
had at least 10 encounters. As most of the reporting was from
inpatient claims (Table 1) this may imply that SEER may have
missed the opportunity to capture treatment information. Fi-
nally, treatment status for individuals in managed care systems
may be more easily identified by the registries as there is a
unified record of incident cancer and treatment but only in-
dividuals with fee-for-service were included in this analysis.
Registries’ ability to capture accurate treatment in-
formation is becoming more difficult over time because of trends
in cancer treatment and also privacy concerns. Although the
Health Insurance Portability and Accountability Act (HIPAA)
Privacy Rule includes provisions to allow mandated cancer re-
porting without patient consent for public health surveillance and
research, it does create confusion on the disclosure of protected
health information by health care providers.23 A survey of North
American Association of Central Cancer Registries (NAACCR)
found that two thirds of registries cited HIPAA as interfering
with nonresearch operations. Among those, 75% reported that
HIPAA was identified as the reason for either ceased case re-
porting from at least 1 source, prevented case finding or auditing,
or interfered with collection of follow-up data.24
Although there are significant limitations found with
the SEER treatment data, there are several possible uses. For
example, researchers used SEER treatment data to select a
cohort of treated individuals.25 Furthermore, SEER treatment
data could be improved by correcting the bias using the POC
data, as done in the study by Mariotto et al,26 and also by
potentially augmenting SEER treatment data using other
larger scale data sources. Linkages between the SEER data
and data sources such as the CRN, state-employee data,
electronic medical records, and insurance billing claims data,
such as Medicare, may provide an opportunity to enhance the
quality of treatment data for individuals with cancer and
possibly provide an opportunity to estimate rates of treatment
receipt in the population. For example, data from CRN’s
Virtual Data Warehouse have been shown to reliably identify
CT as treatment for breast,21,27 colorectal,21 lung,21 and
ovarian28 cancer. Additional benefits to these data are that
they include pharmacy data, individuals under 65 years of
age, and those receiving treatment in HMOs.
In conclusion, caution should be taken when using
treatment information from the SEER data. As the sensitivity
of SEER data to identify treatment was consistently low,
these data cannot be used to accurately describe the pro-
portion of individuals in the population who received treat-
ment. In addition, comparisons between individuals who
received and did not receive treatment based on the SEER
data would be biased. In contrast, the PPV was high for most
cancer sites suggesting that SEER treatment data could be
used reliably to identify a cohort of individuals with cancer
who received treatment. RT data are currently available in
the public-use SEER research data file. CT and HT data are
not publically available but approval may be granted upon
special data request to the SEER program. Our findings can
inform investigators about potential uses of the CT and HT
Medical Care  Volume 54, Number 9, September 2016 SEER Treatment Data Compared With Medicare
Copyright r 2014 Wolters Kluwer Health, Inc. All rights reserved. www.lww-medicalcare.com | e63
data, albeit limited. Finally, NCI is currently investigating
linkages to the SEER data, such as Medicare data, that could
be used to supplement SEER treatment information leading
to more accurate and complete information about treatment
for individuals with cancer.
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